

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/956,940	09/21/2001	Barton F. Haynes	1579-601	4369
. 75	90 12/03/2002			
Nixon & Vanderhye P.C.			EXAMINER	
8th Floor 1100 N. Glebe Rd.			SCHWADRON, RONALD B	
Arlington, VA	22201		ART UNIT	PAPER NUMBER
			1644	
			DATE MAILED: 12/03/2002	

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

Applicant(s)

09/956,940

Haynes

Examiner

Ron Schwadron, Ph.D.

Art Unit 1644



The MAILING DATE of this communication appears on the cover sheet with the correspondence address							
Period f	for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.							
- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.							
If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status							
1) 📙	Responsive to communication(s) filed on			·			
2a) 🗌	This action is FINAL . 2b) ☐ This act	ion is non-final.					
3) 🗆	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.						
Disposi	Disposition of Claims						
4) 💢	Claim(s) 1-31			is/are pending in the application.			
4	la) Of the above, claim(s)			is/are withdrawn from consideration.			
5) 🗆	Claim(s)			is/are allowed.			
6) 🗌	Claim(s)			is/are rejected.			
7) 🗌	Claim(s)			is/are objected to.			
8) 💢	Claims <u>1-31</u>	are	subjec	t to restriction and/or election requirement.			
Application Papers							
9) The specification is objected to by the Examiner.							
10)	10) \square The drawing(s) filed on is/are a) \square accepted or b) \square objected to by the Examiner.						
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11)	The proposed drawing correction filed on	is:	a) 🗌	approved b) \square disapproved by the Examiner.			
	If approved, corrected drawings are required in reply to this Office action.						
12)	2) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120							
	13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) 🗆	a) All b) Some* c) None of:						
	1. Certified copies of the priority documents have been received.						
	2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).							
*See the attached detailed Office action for a list of the certified copies not received.							
14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).							
a) The translation of the foreign language provisional application has been received. 15) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)							
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) Paper No(s).							
	rtice of Draftsperson's Patent Drawing Review (PTO-948)			nt Application (PTO-152)			
3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 6) Other:							
				I			

Serial No. 09/956940 Art Unit 1644

- 1. Restriction to one of the following inventions is required under 35 U.S.C. § 121:
- I. Claims 1-15 are drawn to a method of inducing immune tolerance to a protein, classified in Class 424, subclass 810.
- II. Claim 16-25 are drawn to a method of facilitating entry of a molecule into a cell, classified in Class 435, subclass 375.
- III. Claims 26 is drawn to a method of treating HIV infection, classified in Class 514, subclass 2.
 - IV. Claims 27-31 are drawn to a conjugate, classified in Class 536, subclass 23.
- 2. The inventions are distinct, each from the other because of the following reason.
- 3. Inventions II and IV are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the conjugate as claimed can be used in a materially different process such as an immunogen for producing antibodies which bind said product.
- 3. The conjugate of Group IV is not used in the method of Groups I or III. Therefore they are novel and unobvious in view of each other and are patentably distinct.
- 4. Inventions I-III are different methods which use different ingredients to achieve different goals. Invention I is drawn to a method of inducing immune tolerance, while invention II is drawn to a method of facilitating entry of a molecule into a cell, and invention III is drawn to a method of treating HIV infection. Therefore they are novel and unobvious in view of each other and are patentably distinct.
- 5. Because these inventions are distinct for the reasons given above and the search required for any group from Groups I-IV are not required for any other group from Groups I-IV and Groups I-IV have acquired a separate status in the art as shown by their different classification

Serial No. 09/956940 Art Unit 1644

and divergent subject matter, restriction for examination purposes as indicated is proper.

6. If applicant elects invention I, the following species election is required.

This application contains claims directed to the following patentably distinct species of the claimed invention.

The method which uses one of the particular receptors recited in claims 8-14 (eg. TSH receptor, etc).

These receptors are functionally and chemically distinct.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.

7. If applicant elects invention II, the following species election is required.

This application contains claims directed to the following patentably distinct species of the claimed invention.

The method which uses a protein or nucleic acid.

These molecules are functionally and chemically distinct.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.

8. Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct,

Art Unit 1644

applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.

Any inquiry concerning this communication or earlier communications from the Examiner 9. should be directed to Dr. Ron Schwadron whose telephone number is (703) 308-4680. The examiner can normally be reached Monday through Thursday from 7:30 to 6:00. A message may be left on the examiners voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the Examiner's supervisor, Ms Christina Chan can be reached on (703) 308-3974. Any inquiry of a general nature or relating to the status of this application should be directed to the Group 1600 receptionist whose telephone number is (703) 308-0196.

> RONALD B. SCHWADRON PRIMARY EXAMINER GROUP 1800 / (~

Ron Schwadron, Ph.D. Primary Examiner Art Unit 1644